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Transaldolase Deficiency: Liver Cirrhosis Associated with a New Inborn
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This article describes the first patient with a deficiency of transaldolase (TALDO1 [E.C.2.2.1.2]). Clinically, the
patient presented with liver cirrhosis and hepatosplenomegaly during early infancy. In urine and plasma, elevated
concentrations of ribitol, D-arabitol, and erythritol were found. By incubating the patient’s lymphoblasts and
erythrocytes with ribose-5-phosphate and subsequently analyzing phosphate sugar metabolites, we discovered a
deficiency of transaldolase. Sequence analysis of the transaldolase gene from this patient showed a homozygous
deletion of 3 bp. This deletion results in absence of serine at position 171 of the transaldolase protein. This amino
acid is invariable between species and is located in a conserved region, indicating its importance for enzyme activity.
The detection of this new inborn error of pentose metabolism has implications for the diagnostic workup of liver
problems of unknown etiology.
Introduction
Polyols, or polyhydric alcohols, are sugar-derived me-
tabolites that are ubiquitous in humans. The origin, met-
abolic fate, and function of most of the polyols are un-
known. Recently, we described a patient suffering from
a cerebral-white-matter disorder and peripheral neurop-
athy of unknown origin (van der Knaap et al. 1999). In
brain and body fluids of the patient, highly elevated lev-
els of D-arabitol and ribitol were found. The strong
brain/cerebrospinal fluid (CSF)/plasma gradient, with
highest levels in brain and lowest levels in plasma, sug-
gested a neurometabolic disorder. The biochemical basis
of this inborn error of polyol metabolism has not yet
been elucidated.
In a research project concerning human polyol metab-
olism and associated inborn errors, we investigated poly-
ols in urine samples from patients suspected of having a
metabolic disorder. In addition, we reviewed all results
of the past 10 years of analyses of sugars and polyols.
In the present study, we report on a new disorder with
involvement of polyol metabolism. The patient, whowas
10 years of age at the time of this study, presented in
early childhood with liver cirrhosis of unknown origin.
Biochemical and molecular-biological studies revealed a
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deficiency of transaldolase (TALDO1 [MIM 602063])
and a mutation in the human TALDO1 gene.
Patient and Methods
Case History
The patient was the first child of healthy, consan-
guineous Turkish parents. She was born after an un-
complicated pregnancy of 39 wk and had a birth weight
of 1,910 g. Soon after birth, she underwent surgi-
cal correction of aortic coarctation. After the surgical
procedure, she manifested mild bleeding problems. An
enlarged clitoris was noted. Within several months,
she developed hepatosplenomegaly. Liver function re-
mained normal (normal levels of aspartate aminotrans-
ferase (ASAT), alanine aminotransferase (ALAT), lactate
dehydrogenase, and g-glutamyltransferase [g-GT] in
plasma), apart from a persisting bleeding tendency with
mildly prolonged prothrombin time (PT) and activated
partial thromboplastin time (APTT). Increase in height
was normal, but weight for height remained just under
the 3d percentile. Her mental and motor development
was normal. Metabolic investigations of her urine
showed mildly elevated concentrations of glycine and
glutamine. Concentrations of organic acids in urine were
normal. Gas-chromatographic analysis of sugars and
polyols, performed to exclude galactosemia, showed
normal concentrations of galactose and galactitol in
urine. In the same analysis, elevated concentrations of
arabitol, ribitol, and erythritol were observed. The anal-
ysis of sugars and polyols in urine was repeated in other
urine samples, always revealing the same abnormalities.
When the child was 2 years of age, additional labo-
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ratory tests were performed because of the hepatosplen-
omegaly. Again, levels of ASAT, ALAT, and g-GT in
plasma were normal. Bile acids were slightly elevated
(19 mmol/liter [control values !6 mmol/liter]). Cerulo-
plasmin was normal. Complement factors were normal.
Results of cytomegalovirus culture in urine, of the Ve-
nereal Disease Research Laboratories test, of tests for
hepatitis A, B, and C, and of tests for anti-HIV anti-
bodies were all negative. Debranching-enzymedeficiency
was excluded in leukocytes. A liver biopsy showed mi-
cronodular liver cirrhosis consisting of nodes of regen-
erating liver cells separated by fibrous septa, little in-
flammatory reaction, and no specific characteristics.
Immunohistochemical staining provided no evidence of
Wilson disease, hemochromatosis, a1-antitrypsin defi-
ciency, or hepatitis B. Electron microscopy showed no
inclusions in the cytosol, therefore providing no evidence
of either a virus infection or a storage disease. Endocrine
studies (dehydroepiandrosterone, androstenedione, and
testosterone in serum) were performed because of the
abnormal clitoris and were normal.
The patient was lost to follow-up. At the age of almost
10 years, she was readmitted to the hospital. Her height
was at the 10th percentile, her weight for height at the
2d percentile. Physical examination revealed many tel-
angiectasias of her skin and an unchanged hepatosplen-
omegaly and enlarged clitoris. The liver had a rock-hard
consistency, and liver size was 7 cm below the costal
margin. Results of neurological examination were nor-
mal. Laboratory investigations, performed over a period
of 1 year, revealed a persistent trombocytopenia (60–63
# 109/liter [control values 150–400# 109/liter]), which
probably was caused by splenic pooling due to the he-
patosplenomegaly. Both APTT and PT were mildly in-
creased, which could be ascribed to decreased produc-
tion of coagulation factors that was due to liver cirrhosis.
Except for nosebleeds, there were no clinical manifes-
tations of the prolonged APTT and PT. Iron-deficiency
anemia was diagnosed, which was corrected by iron sup-
plementation. Cholesterol was found to be low (2.1–2.5
mmol/liter [control values 3.1–5.2 mmol/liter]) on sev-
eral occasions, withHDL being 1.25mmol/liter andwith
LDL being 0.7 mmol/liter. Alkaline phosphatase in
plasma was normal (125–160 U/liter [control values
60–325 U/liter), g-GT was elevated (106 U/liter [control
values 5–35 U/liter]) on one occasion but normalized.
Transaminases in plasma were normal (ASAT, 22 U/liter
[control values !40 U/liter]; ALAT, 15 U/liter [control
values !45 U/liter]). Bile acids were elevated (23 and 24
mmol/liter [control values !6 mmol/liter), whereas bili-
rubin was normal. On two occasions elevated ammonia
(103 and 89 mmol/liter [control values !50 mmol/liter])
was found , whereas on another occasion the ammonia
level was normal (32 mmol/liter). Echo-doppler investi-
gations showed an enlarged liver with a reflection pat-
tern consistent with cirrhosis. The flow in the portal area
and in the hepatic vein was normal. Spleen size was 14.5
cm.
A range of inborn errors of metabolism—peroxisomal
diseases, cholesterol biosynthesis defects, congenital dis-
orders of glycosylation, and fatty-acid–oxidation de-
fects—were excluded. Analysis of sugars and polyols in
urine revealed the same abnormalities as had been found
both during the neonatal period and at the age of 2 years
(table 1). Proton–magnetic-resonance spectroscopy of
the brain at the age of 10 years revealed no abnormal-
ities; in particular, there were no abnormal resonances
in the sugar-and-polyol region of the spectrum (3.5–4.0
parts/million). Informed consent for the biochemical and
molecular studies was obtained from the patient’s father.
Analysis of Sugars and Polyols in Body Fluids
Sugars and polyols in urine, plasma, and CSF were
assessed according to a method described elsewhere (Jan-
sen et al. 1986). For urine, reference ranges were obtained
from the literature (Jansen et al. 1986). The age groups
0–3 mo, 3–12 mo, and 1–2 years were combined into
one group, since no significant age dependence up to the
age of 2 years was reported. Reference ranges for ribose,
xylulose, ribitol, arabitol, and erythritol in plasma and
CSF were determined in our laboratory. The plasma sam-
ples were obtained from children of different ages. In
none of the plasma samples were the sugars and polyols
detectable, a result that is in line with that in the literature
(Kusmierz et al. 1989). We used 42 CSF samples from
children under investigation for an inborn error of me-
tabolism, to determine control values for sugars and poly-
ols. We included only samples from patients in whom no
biochemical abnormalities were found. Neither age de-
pendence nor sex dependence was found for ribose, xy-
lulose, arabitol, and erythritol. Separate quantification of
D- and L-arabitol was achieved by gas-chromatography
mass spectrometry using a chiral chromatography column
(Chiraldex; Chrompack). Reference values for D- and L-
arabitol were obtained in our laboratory.
Transketolase and Transaldolase Assays
To evaluate the possibility of a defect in the pentose
phosphate pathway, we developed an assay to determine
the activities of both transketolase and transaldolase in
erythrocytes and cultured lymphoblasts. Ribose-5-phos-
phate, which was used as the substrate, is rapidly con-
verted into ribulose-5-phosphate and xylulose-5-phos-
phate by the cell system, providing the second substrate
of transketolase (fig. 1) (Brownstone and Denstedt 1961).
In the transketolase reaction, sedoheptulose-7-phosphate
and glyceraldehyde-3-phosphate are formed, which are
further converted by transaldolase. The reaction products
of the transaldolase reaction are erythrose-4-phosphate
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Table 1
Concentrations of Pentoses, Pentitols, and Erythritol in Body Fluids of the Patient, Compared with Reference Values
Patient !2 Years
of Age (3 Samples)
Controls 0–2 Years
of Age ( )np 31
Patient 10–11 Years
of Age (4 Samples)
Controls 6–15 Years
of Age ( )np 10
Urine (mmol/mol creatinine):
Xylulose 18–61 !5 !5–11 !5
Ribose 21–38 !5 8–14 !5
Arabitol 403–757 27–99 89–542 (D), 10–41 (L) 28–87 (D), 23–43 (L)
Ribitol 235–338 7–24 54–313 4–11
Erytritol 470–883 58–192 90–629 35–179
Patient 10–11 Years








Patient 10 Years of








a Analyzed in only 1 sample; in the other sample, total arabitol was 16 mmol/liter (that in controls was !5 mmol/liter).
b Analyzed in only 5 samples. Total arabitol in the patient was 34 mmol/liter (that in 45 controls was 9–39 mmol/liter).
and fructose-6-phosphate. Further conversion of fruc-
tose-6-phosphate by phosphohexose isomerase yields glu-
cose-6-phosphate. Gas chromatography with nitrogen
phosphorous detection was used to monitor the reaction
products.
EDTA blood was centrifuged for 10 min at 1,500 g
at room temperature. Plasma was removed, and eryth-
rocytes were washed with an equal volume of saline. To
400 ml of washed erythrocytes, 800 ml of ice-cold de-
mineralized water was added for lysis. After 15 min
incubation at room temperature, an aliquot of 225 ml
was taken for the enzyme assay. Lymphoblasts were ob-
tained by Epstein-Barr–virus transformation of isolated
peripheral blood B-lymphocytes. The lymphoblasts were
cultured under standard conditions. For the transketo-
lase-transaldolase enzyme assay, lymphoblasts from a
75-cm2 culture flask were harvested and were homog-
enized by sonification. The protein content of the lym-
phoblast homogenate was determined by the bicinchon-
inic acid method (Smith et al. 1985).
The transketolase and transaldolase reaction was per-
formed in a final volume of 600 ml, with final concen-
trations of 45 mM Tris HCl buffer, 21 mM Mg2, 0.1
mM thiamine pyrophosphate, and 4 mM ribose-5-phos-
phate (all from Sigma). The incubation mixture was
placed at 37C, and 50-ml samples were taken at 0
and 120 min. To the 50-ml incubation samples, 50 ml of
1 mM deoxyribose-5-phosphate (internal standard)
(Sigma) in methanol was added, after which the samples
were stored for 30 min at 20C. The samples were
centrifuged for 10 min at 1,500 g at room temperature.
The supernatants were evaporated to dryness, at 40C,
under a gentle stream of nitrogen. Then 200 ml of pyridine
(Merck) and 4 mg of methoxyamine (Sigma) were added,
after which the samples were left for 30 min at 40C. The
samples then were evaporated again, and 100 ml of N,O-
bis(trimethylsilyl)-trifluoroacetamide (Pierce) was added.
After derivatization at 90C for 30 min, the samples were
subjected to gas chromatography (CP-sil 19 CB column;
Chrompack). The temperature program was 150C for 1
min, increasing by 10C/min to 325C. The temperature
of the nitrogen phosphorus detector was 325C. This de-
tector was used because its high sensitivity to compounds
containing nitrogen and/or phosphor results in selective
signals for sugar phosphates. The identities of the signals
in the chromatogram were determined by use of com-
mercially available standard compounds (glyceraldehyde-
3-phosphate, fructose-6-phosphate, erythrose-4-phos-
phate, and sedoheptulose-7-phosphate [all from Sigma]
and glucose-6-phosphate [Boehringer-Mannheim]). The
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Figure 1 Schematic representation of pentose phosphate pathway (PPP) and presumed reactions leading to pentoses (ribose and xylulose),
pentitols (D-arabitol and ribitol), erythrose, and erythritol.
enzyme assay was validated by use of commercially avail-
able transketolase and transaldolase enzymes (Sigma).
Molecular Analysis of Transaldolase
The cDNA sequence as well as the gene structure of
human TALDO1 have recently been reported (Banki et
al. 1994) (GenBank accession number NM_006755).
cDNAwas synthesized from total RNAderived from lym-
phoblasts from the patient, by Omniscript reverse tran-
scriptase (RT) (Qiagen). One set of transaldolase-specific
primers was used to amplify TALDO1 cDNA, by RT-
PCR using Hot Startaq (Qiagen). The 1,100-bp cDNA
was bidirectionally sequenced by use of a sequencing kit
(BigDye terminator; PE Biosystems) and was analyzed on
an automated DNA sequencer (ABI 310; PE Biosystems),
according to the manufacturer’s protocols. The mutation
was confirmed by direct sequencing of PCR-amplified
exon 5. (Primer sequences will be provided on request
from the corresponding author.)
Results
Metabolite Analyses
Table 1 shows the ranges of concentrations of pen-
toses, arabitol, ribitol, and erythritol in urine, plasma,
and CSF samples from our patient. In urine samples
obtained during the neonatal period, elevated concen-
trations of the pentitols D-arabitol and ribitol and of the
tetritol erythritol were noted. The presumed pentose pre-
cursors ribose and xylulose were slightly elevated. Other
sugars and polyols, including sorbitol, galactose, gal-
actitol, and mannitol, were present in normal amounts.
Repeated analysis of sugars and polyols at the ages of
3 and 10 years revealed the same profile of abnormali-
ties. A consistent finding was a large, unknown peak in
the chromatogram. Themass spectrum of this compound,
obtained in the chemical-ionization mode, showed a sig-
nal at a mass:charge ratio of 660, which corresponds to
the expected signal of the trimethylsilyl derivative of se-
doheptulose. Since sedoheptulose is not commercially
available, the exact nature of the unknown peak could
not be established.
In both of two plasma samples obtained when the
patient was 10 years of age, erythritol, D-arabitol, and
ribitol were elevated. The concentrations of pentoses in
plasma were normal.
In CSF, obtained at the age of 10 years, erythritol was
normal, whereas ribitol and D-arabitol were mildly
elevated.
Enzyme Studies
Figure 2 shows the formation of phosphate sugars by
lymphoblasts from the patient and from a control, after
2 h of incubation with ribose-5-phosphate. Sedoheptu-
lose-7-phosphate and glyceraldehyde-3-phosphate for-
mation could be observed in both the patient and the
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Figure 2 A, Transketolase and transaldolase activity in cultured lymphoblast homogenates. Activity was measured by monitoring the
production of glyceraldehyde-3-phosphate (G3P), sedoheptulose-7-phosphate (S7P), fructose-6-phosphate (F6P), and glucose-6-phosphate (G6P)
from ribose-5-phosphate, by gas chromatography with nitrogen phosphorus detection. Five different control cell lines were analyzed. For the
patient, the mean value of two independent experiments is presented. Results are expressed as percentage of the signals obtained in the controls.
Error bars indicate SD in the results of the control cell lines. G3Pp glyceraldehyde-3-phosphate; G6Pp glucose-6-phosphate.B,Chromatogram
showing results obtained in transketolase-transaldolase assay in control lymphoblasts and lymphoblasts from the patient, illustrating the formation
of G3P and S7P and the absence of formation of F6P and G6P in the patient. E4P p erythrose-4-phosphate; 5P p ribose-5-phosphate.
controls, showing that transketolase activity is present.
In the controls, formation of fructose-6-phosphate was
found, whereas this product of the transaldolase reaction
remained absent in the patient. Furthermore, the signal
of sedoheptulose-7-phosphate in the patient was signif-
icantly higher than that in the controls, suggesting a
decreased conversion of this compound in the patient’s
cells. Also in erythrocytes, a deficiency of transaldolase
was found (results not shown).
Detection of the Mutated Transaldolase Gene and
mRNA
Sequence analysis of full-length TALDO1 cDNA am-
plified by RT-PCR demonstrated a homozygous deletion
of 3 bp (nucleotides 561–563) in the patient, which was
confirmed by DNA sequence analysis of exon 5. The
deletion results in loss of serine 171 in the transaldolase
protein, as shown in figure 3. Sequence analysis of DNA
from the father showed the presence of both the wild-
type allele and an allele with the same deletion as was
found in the patient. Thus, the father was a carrier of
TALDO1 deficiency. The mother was not available for
investigations.
Discussion
This article has described a new inborn error in the pen-
tose phosphate pathway: transaldolase deficiency. The
pentose phosphate pathway has two metabolic functions:
(1) generation of nicotinamide adenine dinucleotide phos-
phate (reduced), for reductive biosynthesis, and (2) for-
mation of ribose, a component of essential biomolecules
such as ATP, DNA, and RNA. Two enzymes, transke-
tolase and transaldolase, reversibly link the pentose phos-
phate pathway to glycolysis. The net result of the con-
certed action of these two enzymes is the conversion of
pentose-5-phosphate into glycolytic intermediates.
In the patient, deficiency of transaldolase resulted in
accumulation of erythritol, D-arabitol, and ribitol. Ap-
parently, inadequate conversion of sugar phosphates
leads to polyol accumulation. This phenomenon is also
seen in galactose-1-phosphate uridyltransferase (MIM
230400) deficiency. In the latter disorder, deficient con-
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Figure 3 A, Mutation in TALDO1 cDNA (GenBank accession
number NM_006755; gi 5803186) of the patient. B, Deletion of 3 bp,
resulting in absence of serine 171 in the transaldolase protein.
version of galactose-1-phosphate results in a secondary
accumulation of galactitol (Jakobs et al. 1995). The
accumulated erythritol in our patient is probably de-
rived from erythrose-4-phosphate. No polyols derived
from one of the other substrates (i.e., fructose-6-phos-
phate, sedoheptulose-7-phosphate, and glyceraldehyde-
3-phosphate) were observed. Fructose-6-phosphate and
glyceraldehyde-3-phosphate can be further metabolized
by glycolysis, which prevents accumulation. Accumu-
lation of sedoheptulose and sedoheptitol could not be
proved, because of analytical limitations. Elevations of
D-arabitol and ribitol in the patient are probably caused
by product inhibition of transketolase.
We investigated TALDO1 cDNA and DNA from the
patient and found a homozygous mutation leading to
the deletion of one amino acid (serine 171). This amino
acid is part of a highly conserved region (Thorell et al.
2000), suggesting that the mutation causes the transal-
dolase deficiency that is found in erythrocytes and lym-
phoblasts. The father of the patient was found to be
heterozygous for the deletion. This observation, in com-
bination with the consanguinity of the parents, suggests
an autosomal recessive inheritance pattern for transal-
dolase deficiency.
Transaldolase is present in many tissues, including
brain (Adams et al. 1995). No isoforms of transaldolase
are known in humans. This suggests that, also in brain
tissue of our patient, transaldolase is mutated and thus
inactive. Surprisingly, this does not result in highly el-
evated concentrations of polyols in brain tissue (as in-
vestigated by proton–magnetic-resonance spectroscopy)
and CSF.
The patient affected with transaldolase deficiency is
distinct from the patient whom we had reported else-
where (Van der Knaap et al. 1999). Clinically, the latter
patient had a cerebral-white-matter disease and poly-
neuropathy. Concentrations of polyols in brain and CSF
were highly elevated, higher than those in plasma and
urine. The transaldolase-deficient patient had no neu-
rological involvement and presented with hepatic symp-
toms. polyol concentrations weremost elevated in urine,
whereas they were close to normal in both plasma and
CSF.
So far, our patient has been the only individual re-
ported with transaldolase deficiency. Therefore, the pos-
sible spectrum of clinical symptoms of this disease can-
not yet be determined. It is highly probable that the
liver cirrhosis and persistent hepatosplenomegaly are
related to the enzyme deficiency. In another inborn error
of metabolism—galactose-1-phosphate uridyltransfer-
ase deficiency—accumulation of both a polyol (galac-
titol) and a sugar phosphate (galactose-1-phosphate) oc-
curs. This disorder is associated with liver cirrhosis. The
accumulation of the sugar phosphates, rather than the
accumulation of polyols, is thought to be important in
the pathophysiology of liver cirrhosis (Holton et al.
2001). By analogy, we hypothesize that, in the transal-
dolase-deficient patient, accumulation of sugar phos-
phates occurs, which may result in cirrhosis.
At present, routine diagnostic workup of patients
with liver cirrhosis does not include assessment of uri-
nary tetritols and pentitols, implying that other patients
with transaldolase deficiency may remain undiagnosed.
We recommend that transaldolase deficiency be in-
cluded in the differential diagnosis of children affected
with liver disease of unknown origin.
In conclusion, we present the first patient affected
with a deficiency of transaldolase. The discovery of this
inborn error has implications for the diagnosis of liver
problems of unknown etiology
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